Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$30.6 million.

  • Dianthus Therapeutics' Free Cash Flow fell 4352.81% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.6 million, marking a year-over-year decrease of 7491.62%. This contributed to the annual value of -$78.3 million for FY2024, which is 11174.7% down from last year.
  • Latest data reveals that Dianthus Therapeutics reported Free Cash Flow of -$30.6 million as of Q3 2025, which was down 4352.81% from -$23.9 million recorded in Q2 2025.
  • Dianthus Therapeutics' Free Cash Flow's 5-year high stood at $16.4 million during Q3 2022, with a 5-year trough of -$30.6 million in Q3 2025.
  • For the 4-year period, Dianthus Therapeutics' Free Cash Flow averaged around -$15.1 million, with its median value being -$15.0 million (2024).
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 7201.74% in 2023, then crashed by 20608.16% in 2024.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Free Cash Flow stood at -$8.9 million in 2022, then crashed by 33.6% to -$11.9 million in 2023, then tumbled by 131.58% to -$27.5 million in 2024, then decreased by 11.23% to -$30.6 million in 2025.
  • Its Free Cash Flow stands at -$30.6 million for Q3 2025, versus -$23.9 million for Q2 2025 and -$27.7 million for Q1 2025.